C. Barbara

NRG1 fusions in non-small cell lung cancer: biology, diagnostics, and emerging HER2/HER3 therapies—a narrative review

Andrea Marini, I. Stasi, Antonio Pellino, Enrico Sammarco et autres

Background and Objective: NRG1 gene fusions are rare but clinically relevant oncogenic drivers in non-small cell lung cancer (NSCLC) and drive tumorigenesis through ligand-dependent activation of HER2/HER3 signaling. In contrast to kinase-driven oncogenic fusions, NRG1 alterations preserve the EGF-like domain that can …

it (code pays fourni par la source)

Neoadjuvant (NA) chemoradiotherapy (CTRT) plus avelumab (Ave) in locally advanced rectal cancer (LARC): 4-year outcomes of the phase II AVANA trial and their association with computational pathology.

Giovanni Trovato, Maria Bensi, Daniele Rossini, Cecilia Villa et autres

3632 Background: The AVANA trial investigated the addition of PD-L1 inhibitor Ave to NA CTRT in LARC. Here, we report long-term survival and explore its association with tumor microenvironment (TME) features assessed through computational pathology. Methods: AVANA is a multicenter, single-arm, phase …

it, gb (code pays fourni par la source)

Mixed endometrial carcinoma: is it time to profile the two components separately?

Gianna Musettini, Paola Pretelli, Andrea Giusti, Samanta Cupini et autres

Objective: Advances in molecular profiling have significantly altered the approach to endometrial cancer (EC). In clinical practice, the assessment of mismatch repair (MMR) proteins and p53 status, combined with the detection of pathogenic POLE mutations, currently categorizes EC into four molecular subgroups …

it (code pays fourni par la source)

Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma

Enrico Sammarco, Antonio Pellino, Eleonora Bona, Azzurra Farnesi et autres

Urothelial carcinoma represents one of the deadliest urological tumors, due to its biological aggressiveness and the ephemeral response to platinum-based chemotherapy of advanced-stage disease. The use of immune checkpoint inhibitors has positively impacted the prognosis of these patients, although only a proportion …

it (code pays fourni par la source)

Immunotherapy‐induced eczema treated with dupilumab

Angelo Massimiliano D’Erme, Cristian Fidanzi, Nicolò Mori, Gianna Musettini et autres

The authors confirm that the data supporting the findings of this study are available from the corresponding author on request.

it (code pays fourni par la source)

Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study

Luigi Coltelli, Chiara Finale, Gianna Musettini, Andrea Fontana et autres

AIMS: To explore the cardiac safety of adjuvant Non-Pegylated Liposomal Doxorubicin (NPL-DOX) plus Cyclophosphamide (CTX) followed by weekly Paclitaxel, in elderly women (≥ 65 years) with high-risk breast cancer. Previously, we described no symptomatic cardiac events within the first 12 months from …

it (code pays fourni par la source)

Psoriasis caused by pembrolizumab treatment in advanced melanoma: A positive prognostic side effect?

Angelo Massimiliano D’Erme, Cristian Fidanzi, Agata Janowska, Giacomo Allegrini et autres

The data that support the findings of this study are available from the corresponding author upon reasonable request.

it (code pays fourni par la source)

O-12 Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study

Lisa Salvatore, Maria Bensi, Salvatore Corallo, Francesca Bergamo et autres

it (code pays fourni par la source)

Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study.

Lisa Salvatore, Maria Bensi, Salvatore Corallo, Francesca Bergamo et autres

3511 Background: Preop CTRT is considered the standard of care in the management of LARC. RT can induce antigen release from a low neoantigen-burden tumor (such as a mismatch repair proficient colorectal cancer) and activate dendritic cells leading to a CD8+ T …

it (code pays fourni par la source)

On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study

Elena Bolzacchini, Graziella Pinotti, Lorenza Bertù, Claudio Verusio et autres

it (code pays fourni par la source)

Treatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO

Daniele Rossini, Sara Lonardi, Carlotta Antoniotti, Daniele Santini et autres

it (code pays fourni par la source)

Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study

Lisa Salvatore, Maria Bensi, Filippo Pietrantonio, Alessandra Boccaccino et autres

it (code pays fourni par la source)